Autonomix Medical shares surge 13.91% premarket after positive pancreatic cancer pain relief data shows 93.75% improvement within 7 days.

Autonomix Medical Inc. (NASDAQ: AMIX) surged 13.91% in premarket trading following the release of positive clinical data demonstrating rapid and durable pain relief in pancreatic cancer patients across all disease stages. The company presented subgroup analysis at the 2026 ASCO Gastrointestinal Cancers Symposium, revealing that 93.75% of patients improved from severe to mild or moderate pain within seven days, with sustained benefits observed at four to six weeks and three months. The treatment, a transvascular RF denervation platform, showed efficacy even in Stage 4 patients with limited options, a key unmet need in oncology. CEO Brad Hauser emphasized the findings’ potential to address a critical gap in pain management for advanced pancreatic cancer. The data underscores Autonomix’s innovative nerve-targeted approach and reinforces its position in a high-growth medical device niche.